Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2 study participants receiving up to 3 doses of Xiaflex (collagenase clostridium histolyticum) showed improvement in change from baseline ifor affected shoulder at Day 95, compared to those study participants receiving placebo was not significant.
Product Name : Qwo
Product Type : Enzyme
Upfront Cash : Inapplicable
January 07, 2022
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable